Behavioral Pharmacology of THC and Beta-Myrcene

Launched by JOHNS HOPKINS UNIVERSITY · Jun 21, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "Behavioral Pharmacology of THC and Beta-Myrcene," aims to understand how two compounds found in cannabis—THC (the main psychoactive ingredient) and beta-myrcene (a terpene that contributes to the aroma)—affect the body when inhaled. The study will look at how these substances are processed in the body and what effects they have. It is currently not recruiting participants.

To be eligible for this study, you need to be between 18 and 55 years old, in good health, and not currently using drugs other than cannabis. You must also pass certain health tests, such as a physical exam and blood pressure check. Women will need to confirm they are not pregnant. Participants can expect to undergo some health screening and will be asked to provide consent to join the study. This research is important as it could help us better understand cannabis use and its effects on health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Have provided written informed consent
• • 2. Be between the ages of 18 and 55
• • 3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
• • 4. Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission
• • 5. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission.
• • 6. Have a body mass index (BMI) in the range of 18 to 36 kg/m2
• • 7. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
• • 8. Have no allergies to any of the ingredients used to prepare vapor (delta 9-THC, myrcene).
• • 9. Demonstrate competency on cognitive performance measures at screening visit (e.g., PASAT score over 75).
• Exclusion Criteria:
• • 1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit;
• • 2. History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
• • 3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
• • 4. Use of a prescription medication (with the exception of birth control prescriptions) within 5 half-lives for that specific drug; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
• • 5. Cannabis use that is inconsistent with protocol requirements.
• • 6. Clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
• • 7. Individuals with anemia or who have donated blood in the prior 30 days